Prognostic value of circulating CD34+ cells in myelodysplastic syndromes

被引：25

作者：

Cesana, Clara ^{[1
,2
]}

Klersy, Catherine ^{[3
]}

Brando, Bruno

Nosari, Annamaria ^{[1
,2
]}

Scarpati, Barbara ^{[1
,2
]}

Scampini, Linda ^{[1
,2
]}

Molteni, Alfredo ^{[1
,2
]}

Nador, Guido ^{[1
,2
]}

Santoleri, Luca ^{[1
,2
]}

Formenti, Marta ^{[1
,2
]}

Valentini, Marina

Mazzone, Antonino

Morra, Enrica ^{[1
,2
]}

Cairoli, Roberto ^{[1
,2
]}

机构：

[1] Osped Niguarda Ca Granda, Dept Transfus Med, Milan, Italy

[2] Osped Niguarda Ca Granda, Div Hematol, Milan, Italy

[3] Fdn IRCCS Policlin S Matteo, Biometry & Clin Epidemiol Serv, Pavia, Italy

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 11期

关键词：

circulating CD34(+) cells; flow cytometry; International Prognostic Scoring System; myelodysplastic syndrome; peripheral blood; prognosis; WHO;

D O I：

10.1016/j.leukres.2008.03.028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We Studied Circulating (C)CD34(+) cells by flow cytometry in 96 patients with myelodisplastic syndromes (MDS) at diagnosis, and in a Subset of 35 cases during follow-up. CCD34(+) Counts were stratified within both International Prognostic Scoring System (IPSS) and World Health Organization (WHO) categories. Counts > 10/mu l were associated with poorer leukemia-free survival, a prognostic value for evolution independent from that of WHO, and a higher progression probability within intermediate-risk IPSS and WHO classes. When serial measurements were performed, Counts > 10/mu l more frequently correlated to evolution. Separating newly diagnosed patients on the basis of 10/mu l cut-off of circulating CD34(+) cells retains prognostic, utility especially in intermediate-risk MDS. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：1715 / 1723

页数：9

共 30 条

[1] PRECURSORS OF COLONY-FORMING CELLS IN HUMANS CAN BE DISTINGUISHED FROM COLONY-FORMING CELLS BY EXPRESSION OF THE CD33 AND CD34 ANTIGENS AND LIGHT SCATTER PROPERTIES [J].

ANDREWS, RG ;

SINGER, JW ;

BERNSTEIN, ID .

JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (05) :1721-1731

[2] PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].

BENNETT, JM ;

CATOVSKY, D ;

DANIEL, MT ;

FLANDRIN, G ;

GALTON, DAG ;

GRALNICK, HR ;

SULTAN, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199

[3]

Brando B, 2000, CYTOMETRY, V42, P327, DOI 10.1002/1097-0320(20001215)42:6<327::AID-CYTO1000>3.0.CO

[4]

2-F

[5] Myelodysplastic syndromes - Coping with ineffective hematopoiesis [J].

Cazzola, M ;

Malcovati, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06) :536-538

[6] Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t;: novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry [J].

Fuchigami, K ;

Mori, H ;

Matsuo, T ;

Iwanaga, M ;

Nagai, K ;

Kuriyama, K ;

Tomonaga, M .

LEUKEMIA RESEARCH, 2000, 24 (02) :163-174

[7]

Gajkowska A, 2006, FOLIA HISTOCHEM CYTO, V44, P53

[8] Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) [J].

Germing, U ;

Hildebrandt, B ;

Pfeilstöcker, M ;

Nösslinger, T ;

Valent, P ;

Fonatsch, C ;

Lübbert, M ;

Haase, D ;

Steidl, C ;

Krieger, O ;

Stauder, R ;

Giagounidis, AAN ;

Strupp, C ;

Kündgen, A ;

Mueller, T ;

Haas, R ;

Gattermann, N ;

Aul, C .

LEUKEMIA, 2005, 19 (12) :2223-2231

[9]

Germing U, 2006, HAEMATOLOGICA, V91, P1596

[10]

Gratama JW, 1998, CYTOMETRY, V34, P128, DOI 10.1002/(SICI)1097-0320(19980615)34:3<128::AID-CYTO3>3.0.CO

← 1 2 3 →